| 靶点: |
MIC90: 6.25 μg/mL (Staphylococci) |
| 体内研究: |
In the thigh infection model with a homogeneous MRSA strain, the bacterial counts in tissues treated with BO3482-cilastatin are significantly reduced in a dose-dependent manner compare with the counts in those treat with vancomycin and imipenem-cilastatin. |
| 参考文献: |
1. Adachi Y, et al. In vitro evaluation of BO-3482, a novel dithiocarbamate carbapenem with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother. 1997 Oct;41(10):2282-5. 2. Nagano R, et al. Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1997 Oct;41(10):2278-81. |
| 溶解性: |
DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.608 ml |
13.04 ml |
26.08 ml |
| 5 mM |
0.522 ml |
2.608 ml |
5.216 ml |
| 10 mM |
0.261 ml |
1.304 ml |
2.608 ml |
| 50 mM |
0.052 ml |
0.261 ml |
0.522 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |